TOP HEADLINES

Featured Story

ThromboGenics spins out cancer R&D, scales down staff amid lackluster Jetrea sales

Disappointing sales of ThromboGenics' only marketed product, Jetrea, have taken their toll on the company's profits this year. To get back in the black, the Belgian company now says it's spinning out its cancer R&D activities to focus on the struggling eye drug.

Band of West Coast biotech insiders pushes oral anticoagulant to PhIII

Some well-known biopharma execs on the West Coast, including Impax Labs founder and former CEO Larry Hsu, have teamed up on a low budget, late-stage program for an oral anticoagulant.

Sanofi appoints Japan exec to lead U.S. pharma ops

Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter)...

Booming Gilead blueprints an overhaul of its campus

After more than doubling its work force over the past 6 years, Gilead is investing part of the fortune it has reaped from HIV drugs as well as the hep C therapy Sovaldi in a complete makeover of its big campus in Foster City, CA.

Round two? Market rumors on a new Pfizer bid for AstraZeneca heat up

The story about a potential new takeover offer for AstraZeneca by Pfizer will not die.

MORE NEWS

From Our Sister Sites

FiercePharma

Specialty drugmakers often find their treatments scrutinized, with critics wondering if they're worth their sometimes high price tags. But what about their CEOs?

FierceMedicalDevices

The latest in a series of guidances explaining and implementing last year's Unique Device Identification final rule is "little more than a regurgitation of information contained in the rule itself, the preamble to the rule, the UDI website, and the Global Unique Device Identification (GUDID) guidance document," wrote medical device law attorney Jennifer Newberger.